Brief: Acadia Pharmaceuticals Announces Top-Line Results From Phase 3 Advance-2 Trial Of Pimavanserin

Acadia Pharmaceuticals

11/03/2024 20:14

March 11 (Reuters) - ACADIA Pharmaceuticals Inc
 ACAD.O :
    * ACADIA PHARMACEUTICALS ANNOUNCES TOP-LINE RESULTS FROM
PHASE 3
ADVANCE-2 TRIAL OF PIMAVANSERIN IN NEGATIVE SYMPTOMS OF
SCHIZOPHRENIA
    * ACADIA PHARMACEUTICALS INC: STUDY DID NOT MEET PRIMARY
ENDPOINT
    * ACADIA PHARMACEUTICALS INC - STUDY DID NOT MEET PRIMARY
ENDPOINT
    * ACADIA PHARMACEUTICALS : SAFETY & TOLERABILITY PROFILE OF
PIMAVANSERIN WAS CONSISTENT WITH PREVIOUS TRIALS, SHOWING LOW
RATE OF ADVERSE EVENTS

Source text for Eikon:  ID:nBwMd5QSa 
Further company coverage:  ACAD.O 

 ((Reuters.Briefs@thomsonreuters.com;))